Posted by Michael Wonder on 26 Jul 2017
Post-market review of pulmonary arterial hypertension medicines – public consultation process
26 July 2017 - The public consultation process on the post-market review of the pulmonary arterial hypertension medicines has now closed.
The Department appreciates the contributions of all organisations and individuals who made a submission.
An additional medicine, riociguat, has been added to the review. The sponsor of this medicine, and stakeholders who have previously provided a submission, were invited to update their submission if required.
